Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.
Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.
Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.
Targeted Oncology offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
The Société française d'angiogenèse is affiliated to the journal.
Original Research Article
Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study
Original Research Article
Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review
To view the rest of this content please follow the download PDF link above.